Pharmacogenomics of paclitaxel

Pharmacogenomics

Volumn 11, Issue 5, 2010, Pages 621-623

  Rodrguez Antona, Cristina ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

Efficacy; Neurotoxicity; Paclitaxel; Pharmacogenetics; Polymorphisms; Taxol

Indexed keywords

CORTICOSTEROID; CREMOPHOR; CYTOCHROME P450 2C8; CYTOCHROME P450 3A5; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

BLOOD TOXICITY; BREAST CANCER; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; GANGLIONEUROPATHY; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYPERSENSITIVITY REACTION; LUNG CANCER; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NOTE; OVARY CANCER; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHARMACOGENOMICS;

CLINICAL TRIALS AS TOPIC; HUMANS; MICROTUBULES; NEOPLASMS; PACLITAXEL; PHARMACOGENETICS;

EID: 77951517312     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.32     Document Type: Note

References (19)

1. Manfredi JJ, Horwitz SB: Vinblastine paracrystals from cultured cells are calcium-stable. Exp. Cell Res. 150, 205-212 (1984).
2. Nogales E, Wolf SG, Downing KH: Structure of the a b tubulin dimer by electron crystallography. Nature 391, 199-203 (1998). (Pubitemid 28092482)
3. Rowinsky EK, Wright M, Monsarrat B, Donehower RC: Clinical pharmacology and metabolism of taxol (paclitaxel): update 1993. Ann. Oncol. 5(Suppl. 6), S7-S16 (1994).
4. Pusztai L: Markers predicting clinical beneft in breast cancer from microtubule-targeting agents. Ann. Oncol. 18(Suppl. 12), xii15-20 (2007).
5. Monzo M, Rosell R, Sanchez JJ et al.: Paclitaxel resistance in non-small-cell lung cancer associated with b-tubulin gene mutations. J. Clin. Oncol. 17, 1786-1793 (1999).
6. Joerger M, Huitema AD, Richel DJ et al.: Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group. Clin. Cancer Res. 13, 6410-6418 (2007).
7. Mielke S, Sparreboom A, Steinberg SM et al.: Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin. Cancer Res. 11, 4843-4850 (2005). (Pubitemid 41557204)
8. Green H, Soderkvist P, Rosenberg P et al.: Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin. Pharmacol. Toxicol. 104, 130-137 (2009).
9. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A: Identifcation of OATP1B3 as a high-affnity hepatocellular transporter of paclitaxel. Cancer Biol. Ther. 4, 815-818 (2005).
10. Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ: Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin. Pharmacol. Ther. 74, 380-387 (2003).
11. Rodriguez-Antona C, Niemi M, Backman JT et al.: Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J. 8, 268-277 (2008).
12. Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001).
13. Smith NF, Marsh S, Scott-Horton TJ et al.: Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin. Pharmacol. Ther. 81, 76-82 (2007).
14. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR: ABCB1 genotype and Pgp expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. 7, 154-179 (2007).
15. Sissung TM, Mross K, Steinberg SM et al.: Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur. J. Cancer 42, 2893-2896 (2006).
16. Leskelä S, Jara C, Leandro-García LJ et al.: Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J. (2010) (Epub ahead of print).
17. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R: Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer. J. Clin. Oncol. 25, 4528-4535 (2007).
18. Seve P, Dumontet C: Is class III b-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 9, 168-175 (2008).
19. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK: MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol. Cancer Ther. (2009) (Epub ahead of print).